PRAME and chronic myelogenous leukemia, BCR-ABL1 positive: Moreover, PRAME expression correlates with higher tumour grade and poorer prognosis in neuroblastoma, urothelial carcinoma, osteosarcoma, head and neck carcinoma, breast cancer, liposarcoma, chronic myeloid leukaemia, and lymphomas21–23.